Browse diseases

…nation strategies, and the generation of cellular therapies for cancer.Ethics Approval Human subjects research was approved by the IRB…

…epresent true breakthroughs in cancer care, delivering cures to cancer patients. However, 75-85% patients show only transient response…

… myeloid, dendritic, and natural killer cells in the context of cancer. In the present study, we have developed a novel NOD-scid IL2rg…

… that limit natural killer (NK) cells as a cellular therapy for cancer include limited numbers in peripheral blood and optimization of…

…file and characterize various cell biology phenomena, including cancer, immunology, and biologic drugs such as antibody therapies, ado…

…Background CCR8 is a potential therapeutic target to treat cancer due to its role in the immunosuppression induced by regulatory …

…Background While checkpoint immunotherapy has revolutionized cancer treatment, responses are observed only in a subset of patients.…

…ls. High-dose IL-2 monotherapy can induce complete responses in cancer patients, but its clinical application is severely limited by a…

…s like rituximab, play a critical role in the treatment of both cancer and autoimmune diseases. The development of novel agents requir…

…ting the advancement of macrophage-targeted immunotherapies for cancer. Our working hypothesis is that in vivo plasticity is the drivi…

…following RT remain poorly understood.Methods Murine colorectal cancer models (MC38 and CT26) were treated with a single high-dose RT …

…totoxicity has been associated to a more favorable prognosis in cancer. Therefore, strategies focusing on enhancing the effector funct…